The patient's CMV serological status affects clinical outcome after T-cell replete haplo-HSCT and post-transplant cyclophosphamide

Bone Marrow Transplant. 2016 Aug;51(8):1134-6. doi: 10.1038/bmt.2016.69. Epub 2016 Mar 21.

Authors

R Crocchiolo¹, L Castagna¹, S Furst², R Devillier², B Sarina¹, S Bramanti¹, J El-Cheikh², A Granata², S Harbi², L Morabito¹, C Faucher², A Rimondo¹, D Girardi¹, B Mohty², B Calmels², C Carlo-Stella¹, C Chabannon², R Bouabdallah², A Santoro¹, N Vey², P J Weiller², D Blaise²

Affiliations

¹ Department of Oncology, Humanitas Clinical and Research Center, Rozzano, Italy.
² Department of Hematology, Institut Paoli-Calmettes, Marseille, France.

PMID: 26999460
DOI: 10.1038/bmt.2016.69

No abstract available

Publication types

Letter
Multicenter Study

MeSH terms

Adolescent
Adult
Aged
Cohort Studies
Cyclophosphamide / therapeutic use
Cytomegalovirus Infections*
Female
Hematologic Neoplasms / complications
Hematologic Neoplasms / mortality
Hematologic Neoplasms / therapy
Hematopoietic Stem Cell Transplantation / adverse effects*
Hematopoietic Stem Cell Transplantation / methods
Hematopoietic Stem Cell Transplantation / mortality
Humans
Lymphocyte Depletion
Male
Middle Aged
Transplantation, Haploidentical / adverse effects*
Treatment Outcome
Young Adult

Substances

Cyclophosphamide